A 2-year post-authorization safety study of high-strength pancreatic enzyme replacement therapy (pancreatin 40,000) in cystic fibrosis

Author： Littlewood James M Connett Gary J Sander-Struckmeier Suntje Henniges Friederike

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.2, 2011-03, pp. : 197-203

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Preparation and In Vivo Efficacy Study of Pancreatin Microparticles as an Enzyme Replacement Therapy for Pancreatitis

By Naikwade Sonali Raosaheb Meshram Rupali Namdeo Bajaj Amrita Narayan

Drug Development and Industrial Pharmacy, Vol. 35, Iss. 4, 2009-04 ,pp. : 417-432

Informa Healthcare

Access to resources Recommend Favorite

A Pathway to Improved Prospective Observational Post-Authorization Safety Studies

By Kiri Victor A.

Drug Safety, Vol. 35, Iss. 9, 2012-09 ,pp. : 711-724

Adis International

Access to resources Recommend Favorite

Evaluation of Post-Authorization Safety Studies in the First Cohort of EU Risk Management Plans at Time of Regulatory Approval

By Giezen Thijs J. Mantel-Teeuwisse Aukje K. Straus Sabine M.J.M.

Drug Safety, Vol. 32, Iss. 12, 2009-12 ,pp. : 1175-1187

Adis International

Access to resources Recommend Favorite

Liver and Pancreatic Disease in Cystic Fibrosis: Clinics and Drug Therapy

Clinical Immunology, Endocrine & Metabolic Drugs, Vol. 3, Iss. 2, 2017-08 ,pp. : 117-129

Bentham Science Publishers

Access to resources Recommend Favorite

Gene therapy for cystic fibrosis

By Boyd A.C.

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 1, 2001-01 ,pp. : 1-15

Informa Healthcare

Access to resources Recommend Favorite